## **Core Concept**
The question pertains to the complications arising from intracranial radiotherapy, specifically focusing on endocrine complications. Intracranial radiotherapy is a treatment modality used for various brain tumors and conditions. It can lead to several side effects due to its impact on the surrounding brain tissues, including endocrine glands.

## **Why the Correct Answer is Right**
Growth hormone (GH) deficiency is recognized as the most common endocrine complication following intracranial radiotherapy. This is because the hypothalamic-pituitary axis, crucial for regulating various hormonal secretions, can be significantly affected by radiation. The hypothalamus and pituitary gland are sensitive to radiation, and their dysfunction can lead to deficiencies in multiple hormones, with GH being particularly susceptible. The mechanism involves damage to the hypothalamic-pituitary axis, leading to reduced secretion of growth hormone-releasing hormone (GHRH) and consequently GH.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While thyroid dysfunction can occur due to radiotherapy, especially if the thyroid gland is within the radiation field, it is not the most common endocrine complication specifically associated with intracranial radiotherapy.
- **Option B:** Adrenal insufficiency can result from radiotherapy if the adrenal glands are affected, but it is less commonly associated directly with intracranial radiotherapy compared to GH deficiency.
- **Option C:** This option is not provided, but based on the correct answer being related to growth hormone deficiency, other options would be incorrect for similar reasons related to their specificity and commonality as complications of intracranial radiotherapy.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that growth hormone deficiency often presents with growth retardation in children and can have metabolic implications in adults. Screening for GH deficiency and other pituitary hormone deficiencies should be considered in patients who have received intracranial radiotherapy.

## **Correct Answer:** D. Growth hormone deficiency.